CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01

Written by Rachel Swansburg

GO BACK TO PRESS RELEASES & MEDIA

Presentation

November 7, 2024

CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01

Rachel Swansburg
Previous

CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers
Next

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting